www.technavio.comenquiry@technavio.com

Global Human Insulin Market 2015-2019

Covered in this Report• The report includes the present scenario and the growth

prospects of the global human insulin market for the period 2015-2019.

• To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of diabetes.

• Technavio's report, Global Human Insulin Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts.

• The report includes a discussion of the key vendors operating in this market.

Global Human Insulin Market

2015-2019

USA – CANADA – UK – CHINA – INDIA

Market Overview• Insulin is a hormone produced by beta cells of the

pancreas that plays a key role in the regulation of blood glucose levels.

• It controls the body systems and regulates the uptake of amino acids by body cells.

• It helps cells absorb glucose from the blood.

• In diabetics, cells stop responding to the insulin produced.

• As a result, glucose in the blood cannot be absorbed by the cells of the body.

• Technavio's analysts forecast the global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019.

To know more aboutGlobal Human Insulin

Market 2015-2019,please mail us at

enquiry@technavio.com

USA – CANADA – UK – CHINA – INDIA

Key Vendors and Regions

• Eli Lilly

• Novo Nordisk

• Sanofi

• Biocon

• Biodel

• Biogenomics

• Boehringer Ingelheim

• Bristol-Myers Squibb

View Our Report: Global Human Insulin Market 2015-2019

• Americas

• EMEA

• APAC

Vendors Regions

USA – CANADA – UK – CHINA – INDIA

Key Findings

• The global human insulin market is characterized by the presence of three major vendors Lilly, Novo Nordisk, and Sanofi.

• Manufacturers such as Biocon, Intas Pharmaceuticals, Wockhardt, Probiomed, Biosidus, 3SBio, and Tonghua Dongbao are however limited to their local markets.

• These local vendors compete with major players by manufacturing generic insulin biosimilar products.

• Vendors are undergoing strategic alliances for the marketing or manufacturing of drugs.

• Many new players are poised to enter this market as the market is witnessing patent expiries and high prevalence of diabetes in emerging economies such as China.

USA – CANADA – UK – CHINA – INDIA

Key Questions Answered in Our Report

• What will the market size be in 2019 and what will the growth rate be?

• What are the key market trends?

• What is driving this market?

• What are the challenges to market growth?

• Who are the key vendors in this market space?

• What are the market opportunities and threats faced by the key vendors?

• What are the strengths and weaknesses of the key vendors?

Have a question of your own about this report?

Ask our Analysts

USA – CANADA – UK – CHINA – INDIA

• Decision makers and influencers in sales & marketing, strategy, product and R&D teams rely on research from Technavio. We have a large and growing base of happy customers worldwide. Our customers include technology suppliers, end users, consulting companies, investment firms and research institutes.

• Technavio was founded in 2003 in London. We have about 300 analysts globally. We cover more than 500 technologies across 80 countries. Traditional media such as Forbes Asia and New York Times, along with other web media portals, like to quote us.

About Technavio

Some of our clients include:ACT Global, Flextronics, Huawei Technologies Co, Infosys, Harris Corporation, Infosys, Intercad, Hidaka Precision Tools & Dies Company, Huawei Technologies Co, American Capital, Analysis Group, Netscout, NTT DoCoMo

USA – CANADA – UK – CHINA – INDIA

View Our Report

Global Human Insulin Market 2015-2019

63 Pages | SKU: IRTNTR6990

For media enquiries,please drop us a mail atmedia@technavio.com

For more on the scope of the report, mail us atenquiry@technavio.com

Thank You!

Mail us at: enquiry@technavio.comYou can visit us at:www.technavio.com

USA – CANADA – UK – CHINA – INDIA